LOGIN  |  REGISTER
Astria Therapeutics
Terns Pharmaceuticals

Amwell to Participate in Upcoming Investor Conference

February 21, 2024 | Last Trade: US$6.98 0.04 -0.57

Boston, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in hybrid care enablement, announced that company executives will participate in the TD Cowen Health Care Conference on Tuesday, March 5 in Boston. 

Ido Schoenberg, M.D., Amwell chairman and co-CEO, and Robert Shepardson, Amwell CFO, will participate in a fireside chat at 10:30 a.m. ET, along with one-on-one meetings throughout the day.  

An audio webcast of the fireside chat will be available at investors.amwell.com

About Amwell   

Amwell is a leading hybrid care, delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/

©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTMand the Amwell Logo are registered trademarks or trademarks of American Well Corporation.   

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page